Direct Diffusion of cis-Diamminedichloroplatinum(H) in Intraperitoneal Rat Tumors after Intraperitonal Chemotherapy: A Comparison with Systemic Chemotherapy

Cancer Research

Volumn 49, Issue 12, 1989, Pages 3380-3384

  Los, Gerrit ^a   de Graaf, Peter W ^a   McVie, J Gordon ^a   Mutsaers, Peter H A ^b   van der Vijgh, Wim J F ^c   Baldew, Glenn S ^d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d Interuniversity Reactor Institute Delft   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ANIMAL CELL; ANIMAL MODEL; ASCITES TUMOR; CANCER CHEMOTHERAPY; DRUG TISSUE LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOCARCINOMA; ANIMAL; CISPLATIN; COLONIC NEOPLASMS; DIFFUSION; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; KINETICS; MALE; RATS; RATS, INBRED STRAINS; SUPPORT, NON-U.S. GOV'T;

EID: 0024339362     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Myers, C. The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin. Oncol., 3:275–284, 1984.
2. Dedrick, R. L., Myers, C. E., Bungay, P. M., and De Vita, V. T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep., 62:1–11,1978.
3. Howell, S. B., Pfeiffle, C. E., Wung, W. E., Olshen, R. A., Lucas, W. E., Yon, J. L., and Green, M. Intraperitoneal cisplatin with thiosulfate protection. Ann. Intern. Med., 97:845–851,1982.
4. Howell, S. B., Pfeiffle, C. E., and Olshen, R. A. Intraperitoneal chemotherapy with mephalan. Ann. Intern. Med., 101:14–18,1982.
5. Jones, R. B., Collins, J. M., Myers, C. E., Brooks, A. E., Hubbard, S. M., Balow, J. E., Brennan, M. F., Dedrick, R. L., and Devita, V. T. High–volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res., 41:55–59,1981.
6. King, M. E., Pfeiffle, C. E., and Howell, S. B. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J. Clin. Oncol., 2:662–669,1984.
7. Ozols, R. F., Young, R. C., Speyer, J. L., Sugarbaker, P. H., Green, R., Jenkins, J., and Myers, C. E. Phase I and pharmacological studies of Adriamycin administrated intraperitoneally to patients with ovarian cancer. Cancer Res., 42:4265–4269,1982.
8. Speyer, J. L., Collins, J. M., Dedrick, R. L., Brennan, M. F., Buckpitt, A. R., bonder, H., De Vita, V. T., and Myers, C. E. Phase I and pharmacological studies of 5-fluorouracil administrated intraperitoneally. Cancer Res., 40: 567–572, 1980.
9. Speyer, J. L., and Myers, C. E. The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res., 74:264–269, 1980.
10. Prestayko, A. W., Crooke, S. T., and Carter, S. U. (eds.). Cisplatin: Current Status and New Developments. New York: Academic Press, Inc., 1980.
11. Von Hoff, D. D., Schilsky, R., Reichert, C. M., Reddick, R. L., Rozencweig, M., Young, R. C., and Muggia, F. M. Toxic effects of cis–dichlorodiammine platinum in man. Cancer Treat. Rep., 63:1527–1531,1979.
12. Ten Bokkel Huinink, W. W., Dubbelman, R., Aartsen, A., Franklin, H., and McVie, J. G. Experimental and clinical results with intraperitoneal cisplatin. Semin. Oncol., 12:43–46,1985.
13. Brenner, D. E. Intraperitoneal chemotherapy: a review. J. Clin. Oncol., 4: 1135–1147,1986.
14. Kerr, D. J., and Kaye, S. B. Aspects of cytotoxic drug penetration with particular reference to anthracyclines. Cancer Chem. Pharm., 19:1–5,1987.
15. Ozols, R. F., Locker, G. Y., and Doroshow, J. H. Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian carcinoma. Cancer Res., 59:3209–3213,1979.
16. McVie, J. G., Dikhoff, T. G. M. H., and Van der Heide, J. Tissue concentration of platinum after intraperitonal cisplatin administration in patients. Proc. Am. Assoc. Cancer Res., 26:162,1982.
17. Zedick, M. S., and Sternberg, S. S. A model system for studies of colon carcinogenesis: tumor induction by a single injection of methylazoxymethanol acetate. J. Natl. Cancer Inst., 53:1419–1421,1974.
18. Vermorken, J. B., van der Vijgh, W. J. F., Klein, I., Gall, H. E., van Groeningen, C. J., Hart, G. A. M., and Pinedo, H. M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusion of cisplatin. Clin. Pharmacol. Ther., 39:136–144,1986.
19. Dikhoff, T. G. M. H., Van der Heide, J. A., and McVie, J. G. Topographic analysis of platinum levels in kidney slices from cisplatin treated patients. Nucl. Instr. Meth., B10/11:639–642,1985.
20. Dikhoff, T. G. M. H., Prins, M., and Hofman, L. J. B. Target preparation of biological specimens for SPIXE measurements. Nucl. Instr. Meth., 197: 129–132,1982.
21. McVie, J. G., Rodenhuis, S., Dubbelman, R., Varossieau, F. J., and Ten Bokkel Huinink, W. W. Clinical pharmacokinetics of intraperitoneal mitox-antrone in ovarian cancer. Proc. Am. Soc. Clin. Oncol., 6:41,1987.
22. Los, G., Mutsaers, P. H. A., van der Vijgh, W. J. F., Van der Hamer, C. J. A., and McVie, J. G. Platinum distribution in intraperitoneal tumors after intraperitoneal or intravenous chemotherapy. Proc. Am. Soc. Clin. Oncol., 6:42, 1987.
23. Hamilton, T. C., Young, R. C., Louie, K. G., Behrence, B. C., McKoy, W. M., Grotzinger, K. R., and Ozols, R. F. Characteristics of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res., 44:3286–3289,1984.
24. Wahl, R., and Piko, C. Intraperitoneal (i.p.) delivery of radiolabelled monoclonal antibody to i.p. induced xenograft of ovarian cancer. Proc. Am. Assoc. Cancer Res., 26:298,1985.
25. Ward, B. G., Wallace, K., Shepherd, J. H., and Balkwill, R. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res., 47: 2662–2667,1987.
26. Litterst, C. L., and Schweitzer, V. G. Increased tissue deposition and decreased excretion of platinum following administration of cisplatin to cispla–tin pretreated animals. Cancer Chem. Phar., 12:46–49,1984.
27. Harrap, K. R., Jones, M., Wilkinson, C. R., Clink, H. M., Sparrow, S., Mitchley, B. C. V., Clarke, S., and Veasy, A. Antitumor, toxic, and biochemical properties of cisplatin and eight other platinum complexes. In: A. W. Prestayko, S. T. Crooke, and S. K. Carter (eds.), Cisplatin: Current Status and New Developments, pp. 193–212. New York: Academic Press, 1980.
28. Blanchley, J. D., and Hill, J. B. Renal and electrolyte disturbances associated with cisplatin. Ann. Intern. Med., 95:628–632,1981.
29. Terheggen, P. M. A. B., Floot, B. G. J., Scherer, E., Begg, A. C., Fichtinger-Schepman, A. J. J., and Den Engelse, L. Immunochemical detection of interaction products of cis-diamminedichloroplatinum(II) (cisDDP) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) with DNA in rodent tissue sections. Cancer Res., 47:6719–6725,1987.
30. Campbell, A. B., Kalman, S. M., and Jacobs, C. Plasma platinum levels relationship to cisplatin dose and nephrotoxicity. Cancer Treat. Rep., 67: 169–172,1983.